AZN — ASTRAZENECA PLC catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

14 verified catalyst event(s) for ASTRAZENECA PLC (ticker AZN). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-07-01 — A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalum · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-07-01 in 9d ESTIMATED	READOUT A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination Wit Phase 2 · Hepatocellular Carcinoma (HCC)	AZN ASTRAZENECA PLC	Durvalumab, Bevacizumab, Transarterial R	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-06 in 14d ESTIMATED	READOUT Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuz Phase 3 · Breast Cancer; HER2-positive; Metastatic	AZN ASTRAZENECA PLC	Trastuzumab deruxtecan, Taxane, Pertuzum	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-07 in 15d ESTIMATED	READOUT To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of i Phase 2 · Lung Cancer	AZN ASTRAZENECA PLC	Osimertinib, Cisplatin or Carboplatin; P	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-07-14 in 22d ESTIMATED	READOUT Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis Phase 3 · Eosinophilic Esophagitis	AZN ASTRAZENECA PLC	Tezepelumab, Tezepelumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-11 in 2mo ESTIMATED	READOUT AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer	AZN ASTRAZENECA PLC	AZD0901, 5-Fluorouracil, Leucovorin, l-l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-14 in 2mo ESTIMATED	READOUT Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to Phase 3 · Erosive Esophagitis	AZN ASTRAZENECA PLC	Nexium 20mg, Nexium 10mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-24 in 2mo ESTIMATED	READOUT A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbocic Phase 3 · ER-Positive HER2-Negative Breast Cancer	AZN ASTRAZENECA PLC	AZD9833, Anastrozole, Anastrozole placeb	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-28 in 2mo ESTIMATED	READOUT A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Phase 1/2 · Non-Small-Cell Lung Carcinoma	AZN ASTRAZENECA PLC	AZD2936	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-09-30 in 3mo ESTIMATED	READOUT A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab Phase 3 · Non-Small Cell Lung Cancer	AZN ASTRAZENECA PLC	Durvalumab, Oleclumab, Monalizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-09-30 in 3mo ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osime Phase 3 · Metastatic Non-small Cell Lung Cancer	AZN ASTRAZENECA PLC	Dato-DXd, Osimertinib, Pemetrexed, Carbo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-19 in 4mo ESTIMATED	READOUT Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Phase 4 · Asthma	AZN ASTRAZENECA PLC	Benralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-27 in 4mo ESTIMATED	READOUT Study of Novel Immunomodulators as Monotherapy and in Combination With Anticance Phase 2 · Hepatocellular Carcinoma, Biliary Tract Cancer	AZN ASTRAZENECA PLC	Volrustomig, Bevacizumab, Lenvatinib, Ri	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-11-13 in 5mo ESTIMATED	READOUT AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia Phase 1/2 · B-cell Acute Lymphoblastic Leukemia (B-ALL)	AZN ASTRAZENECA PLC	AZD0486	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change

Past

Date	Event	Company	Drug	Official source & verification
2026-06-12 10d ago CONFIRMED	APPROVED TRUQAP	AZN ASTRAZENECA PLC	TRUQAP	openFDA (drugsfda) ↗ ✓ Source-checked 2026-06-22 Actual/recorded date